Apyx Medical Corporation (NASDAQ: APYX) Q2 2025 Earnings | 08/08/2025

11 days ago

27:31

Inside Ticker

Earnings Calls

AI Summary

Summary of Apyx Medical Corporation Q2 2025 Earnings Call

Date: August 8, 2025
Participants:

Charlie Goodwin (President & CEO)
Matt Hill (CFO)
Jeremy Pfeffer (Moderator, LifeSci Advisors)

Key Highlights:

1. Financial Performance (Q2 2025):

Revenue: $11.4M (down 6% YoY from $12.1M), driven by:
- Advanced Energy Segment: $9.7M (flat YoY).
- OEM Segment: $1.7M (down 29% YoY).
Gross Margin: 62.3% (up slightly from 61.7% YoY).
Net Loss: $3.8M (improved from $6.6M YoY).
Cash & Equivalents: $29.3M (vs. $31.7M at year-end 2024).
Cash Burn: Reduced to $1.2M (vs. $4.3M YoY).

2. Strategic & Operational Updates:

Leadership Expansion:
- John Featherstone (20+ yrs in aesthetics) hired to lead North American sales.
- Simon Davies (ex-Vaser) to lead Europe & Asia sales.
Renuvion Growth:
- Strong traction in skin tightening, especially for post-GLP-1 weight loss patients (15M+ users in U.S.).
- Highlighted at Miami Swim Week with patient success stories.
- Launched in China via Glammoon Medical (early demand "exceeded expectations").
Aon System Launch:
- FDA-cleared in May 2025; soft launch underway with 20 systems placed via Ambassador Program.
- Pre-orders exceeding expectations; full commercial rollout begins September 2025.
- Combines Renuvion, liposuction, fat transfer, and electrocoagulation into one platform.

3. Updated 2025 Guidance:

Total Revenue: $50–52M (up from prior $47.6–49M).
- Advanced Energy: $42–44M (up from $39.6–41M).
- OEM: ~$8M (down from $9.5M in 2024).
Gross Margins: ~60%.
Operating Expenses: ≤$40M.
Cash Runway: Expected to fund operations through 2027.

4. Market Trends & Outlook:

GLP-1 Impact: Rising demand for body contouring post-weight loss.
Aesthetics Market Recovery:
- Capital equipment spending remains subdued industry-wide, but Aon demand defies trend.
- China entry via Glammoon (5,000+ plastic surgeons) seen as key growth driver.
Seasonality Shift:
- Typical Q3 dip may be offset by Aon shipments; strong Q4 expected.

Key Takeaways:

Turnaround Underway: Cost cuts reduced losses; Aon and Renuvion poised to accelerate growth.
Innovation Driving Demand: Aon’s integrated platform resonating with surgeons.
Global Expansion: China launch and new commercial hires to fuel international growth.
2025 Catalyst: Full-scale Aon rollout and Renuvion adoption in GLP-1 patient population.

About this video

Apyx Medical Corporation reported its second-quarter 2025 financial results, with total revenue declining 6% year-over-year to $11.4 million, down from $12.1 million in Q2 2024. Revenue from the Advanced Energy segment remained stable at $9.7 million, while the OEM segment experienced a 28.5% decrease to $1.7 million, impacted by lower sales volume under existing supply agreements. The company significantly reduced its net loss attributable to stockholders by 42% to $3.8 million, or $0.09 loss per share, compared to a $6.6 million loss, or $0.19 per share, in the same quarter last year. Adjusted EBITDA loss improved by 54% to a $2.0 million loss, reflecting operational efficiencies and cost management. Operational highlights included the successful launch of the AYON Body Contouring System™ to key surgeons in critical markets and the initiation of commercial sales of Renuvion® in China, generating strong clinical interest and early procedures. AYON received FDA 510(k) clearance, and the company secured preorders during the quarter with shipments expected to continue through the second half of 2025. Management raised full-year 2025 revenue guidance to a range of $50.0 million to $52.0 million, up from prior estimates, driven by AYON presales momentum and international growth, particularly in China. Operating expenses decreased by $3.4 million year-over-year, supporting improved loss metrics. Risks include ongoing competitive pressures, the need to scale commercialization effectively, and uncertainties in global market dynamics. However, the company remains optimistic about its growth prospects, with an expanding product portfolio and strategic international market entry. About Inside Ticker: Inside Ticker delivers timely, in-depth financial news and earnings analysis to empower investors with actionable insights on global companies across sectors. For comprehensive video analysis and real-time updates, visit https://www.insideticker.com/. #ApyxMedicalCorporation #APYX #Q22025 #Earnings #FinancialResults #Revenue #NetLoss #AdjustedEBITDA #AdvancedEnergy #OEM #AYONBodyContouring #Renuvion #FDAApproval #ChinaMarket #CommercialLaunch #MedicalDevices #BodyContouring #RevenueGrowth #CostManagement #OperationalEfficiency #InternationalExpansion #HealthcareInnovation #InvestorUpdates #InsideTicker

Important Note: The stock market is inherently unpredictable, and forecasts are subject to change based on various factors, including economic conditions and company performance. Always consult multiple sources and consider professional advice before making investment decisions.

AI-Powered Financial Analysis This analysis uses real-time market data. While we strive for accuracy, always verify important financial information and consult with qualified financial professionals before making investment decisions. Past performance does not guarantee future results.